Acquired vs. Developmental: When ADHD-Like Features Might Be Reversible
Parts 1–3 examined mechanisms that can produce ADHD-like features: a prefrontal energy deficit, an immune-neuroinflammatory strand, and a dopamine-Nrf2-NLRP3 axis. This final part asks a different and clinically consequential question:
When ADHD-like features are present, are they necessarily present from development — or can some of them be acquired, and therefore reversible?
The answer matters because a feature that is acquired may respond to treatment of its cause, whereas a feature that is developmental wiring generally will not. Conflating the two produces both false hope and missed opportunities.
The series separates what we know from what our research adds. The established background includes the finding that adult ADHD is often not a straightforward continuation of childhood ADHD Asherson and Agnew-Blais (2019), and — from the wider neuroimmunology literature our project draws on — that neuroinflammation and disrupted sleep can degrade cognitive function. What our research adds is the specific reading — that some ADHD-like features are acquired and reversible with treatment of their underlying cause, in contrast to stable developmental wiring. That reading is a registered speculation, not an established finding.
1 The key finding: adult-onset ADHD is not simply childhood ADHD persisting
The most consequential finding in the field is that much adult ADHD does not appear to be a straightforward continuation of childhood ADHD — though the current picture is more nuanced than the earliest landmark finding suggested.
A landmark longitudinal study that followed a large birth cohort into adulthood found that the majority of adults who met criteria for ADHD in their twenties had not had ADHD as children — and, strikingly, that most children with ADHD had not continued to meet full criteria as adults (Moffitt et al. 2015). Only a small fraction of childhood ADHD persisted as adult ADHD.
That finding sparked a debate that has since refined the picture. A closer look at the same phenomenon — including repeated comprehensive assessments of a comparison group from ages 10 to 25 — found that most apparent adult-onset ADHD is adolescent-onset (ages 12–16), not de novo adult-onset, and that in many cases the symptoms reflect a missed childhood presentation, a comorbid disorder, or the cognitive effects of substance use rather than a genuinely distinct adult-onset syndrome Asherson and Agnew-Blais (2019). Retrospective recall of childhood ADHD symptoms is itself unreliable — accuracy only about 55% (Breda et al. 2020) — which means some reported “adult onset” is really forgotten childhood onset.
So the current, more careful conclusion is a mix: some adult ADHD is genuinely adolescent-onset; some reflects missed or misrecalled childhood symptoms; some is explained by substance use or other comorbidity. A clean “distinct adult-onset syndrome, appearing out of nowhere” is now the minority reading, not the consensus.
An honest caveat: this “mix” conclusion rests on a small US comparison cohort (the MTA local normative comparison group, n = 239) rather than a population-grade birth cohort, and two of the key studies share a research lineage, so the evidence is a partly self-referential cluster rather than independent replication. The question is therefore best treated as open, not settled — a point the rest of this article’s hedging reflects.
The clinical implication is still direct: an adult who develops ADHD-like symptoms in adulthood is not necessarily reliving an unbroken childhood condition. They may be experiencing an acquired or adolescent-onset process — one that deserves investigation of its cause, not a shrug toward “lifelong wiring.” But the degree to which that process is truly independent of childhood neurodevelopmental risk, rather than a missed childhood presentation, remains unresolved.
2 Three architectures of the overlap
Our research frames the ADHD-chronic-fatigue relationship through three possible architectures:
Architecture A — shared vulnerability. A common upstream factor — genetic, immune, or developmental — predisposes a person to both ADHD and chronic fatigue independently. The co-occurrence is a selection artifact: the same vulnerability produces both. The genetic architecture of the neurodevelopmental conditions supports this: ADHD and autism share a large fraction of their genetic influences Cross-Disorder Group of the Psychiatric Genomics Consortium (2013).
Architecture B — secondary cascade. The disease process — neuroinflammation, dopaminergic depletion, autonomic dysfunction — produces ADHD-like neuropsychiatric phenotypes in people who would not otherwise have developed them. The ADHD arises because of the illness, not alongside it.
Architecture C — bidirectional amplification. ADHD and the illness each worsen the other — sleep disruption, energy depletion, and stress compound in a loop.
The architectures are not mutually exclusive, and the temporal data matter: when ADHD is documented before fatigue onset — as in the studies where childhood ADHD predicts later chronic fatigue Quadt et al. (2024) — Architecture A or C is supported. Architecture B (acquired ADHD from the illness) applies to a subset of patients who develop new-onset inattention after the illness begins — though the population-level evidence cautions that much apparent “new onset” may be unmasking of pre-existing subclinical neurodivergence rather than true acquisition (see the honest limits below).
3 The mechanism: disrupted interoception and neuroinflammation
Two proposed routes to acquired ADHD-like features:
Interoceptive disruption. The brain maintains a balance between its predictions about the body and the sensory evidence the body sends back. Acquired features are thought to involve corrupted lower-level signals — brainstem and thalamocortical pathways failing to deliver accurate bodily information. The brain compensates by tightening its priors, producing an outward picture of inattention and difficulty regulating arousal. The computational locus differs from developmental ADHD, and so should the response to treatment.
Neuroinflammation and microglial activation. Sustained neuroinflammation degrading prefrontal, mesolimbic, and thalamocortical circuits can be sufficient to produce ADHD-like features in people whose pre-illness neurodevelopment was intact — the registered speculation examined in Part 2. If this cascade is the proximate cause, then interventions targeting neuroinflammation should partially reverse these secondary features — a testable and not-yet-tested prediction.
4 The test: context-dependence
Because the two routes differ in stability, they can be told apart empirically:
If acquired ADHD-like inattention shows the same trait stability and context-independence as developmental ADHD — persisting unchanged and not correlating with markers of neuroinflammation — the acquired model is not supported.
In other words: developmental inattention is always there. Acquired inattention should fluctuate with the underlying process (inflammation, metabolic state) and should improve when that process is treated.
5 The honest limits
- The acquired model is explicitly speculative — a registered hypothesis with low confidence — and a simpler explanation (inflammation directly causing both the symptoms and the underlying process) may account for the findings without any interoceptive framework.
- None of the theoretical components has been directly validated in this context.
- The distinction between acquired and developmental is not yet usable at the bedside: no test currently separates the two in an individual patient.
- Even if some features are acquired and reversible, this does not mean “ADHD can be cured.” It means a subset of the symptom burden in some people may respond to treating its cause.
- The finding that adult ADHD is often adolescent-onset or reflects missed childhood symptoms, rather than a clearly distinct adult-onset syndrome Asherson and Agnew-Blais (2019), establishes a difference between onset groups but does not by itself prove that group is reversible — only that it did not begin in childhood.
- The largest population-grade test found no infection-driven effect. A 20-year national cohort found no independent effect of COVID-19 on ADHD diagnosis or treatment rates (Shkalim Zemer et al. 2024), and the post-COVID rise in ADHD medication is consistent with catch-up diagnosis rather than new onset (Gimbach et al. 2024). This is the strongest counterweight to the “acquired from the illness” architecture (Architecture B): at population scale, infection does not appear to create new ADHD. The honest reading is that most post-infectious attention difficulty reflects unmasking of pre-existing (often subclinical) neurodivergence or symptom overlap, rather than de novo acquisition — though a narrow acquired subset cannot be excluded by the population data.
6 The clinical consequence — and the harm of getting it wrong
The reason this distinction matters clinically:
- If acquired features are dismissed as “just ADHD”, a treatable underlying process (inflammation, a metabolic deficit, disrupted sleep) goes unaddressed.
- If developmental features are treated as acquired and reversible, patients are offered treatments that will not work, and may blame themselves when they don’t.
- The reverse mislabeling also occurs. A “late-game fader” pattern — post-exertional cognitive fog that mimics the ADHD-inattentive type — can be misread as ADHD and trigger evaluation for an attention disorder, when the underlying issue is energy-driven (ATP-limited) rather than motivation-driven, and worsens with exertion rather than persisting constantly. Both directions of the error send the patient down the wrong treatment path.
The honest position is that acquired ADHD-like features should be supported, not pathologized — and the underlying modifiable drivers (sleep, inflammation, iron, energy) should be addressed regardless of the label, because they affect overall wellbeing even when the core developmental wiring is unchanged.
7 What to take away
Some ADHD-like features — inattention, impulsivity, executive difficulty — may be acquired after development rather than built in from it. The finding that adult ADHD is often not a straightforward continuation of childhood ADHD Asherson and Agnew-Blais (2019) supports this possibility. If such features are acquired, they should be context-dependent and potentially reversible with treatment of the underlying cause: neuroinflammation, metabolic disturbance, or sleep disruption.
The encouraging part: this means a meaningful fraction of the daily symptom burden in some people may be addressable without claiming to “fix” ADHD itself.
The honest part: this is a low-confidence hypothesis, and the decisive test — showing that acquired inattention fluctuates with underlying inflammation while developmental inattention does not — has not been run.
This concludes the four-part series on the biology of ADHD. Part 1 examined the prefrontal-energy model and the multi-pathway treatment hypothesis, Part 2 the immune and neuroinflammatory strand, Part 3 the dopamine-Nrf2-NLRP3 axis, and Part 4 the distinction between acquired and developmental features. See the series landing page.
This article reflects research hypotheses with explicit, low confidence — not established clinical fact. Discuss any medical decision with a qualified clinician.